Hereditary transthyretin amyloidosis: a model of medic

Nature Reviews Neurology

15, 387-404

DOI: 10.1038/s41582-019-0210-4

Citation Report

#	Article	IF	Citations
1	Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nature Communications, 2019, 10, 5008.	5.8	127
3	Expanding the spectrum of transthyretin amyloidosis. Muscle and Nerve, 2020, 61, 3-4.	1.0	2
4	Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran. Molecular Diagnosis and Therapy, 2020, 24, 49-59.	1.6	35
5	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology, 2020, 267, 703-712.	1.8	35
6	Kidney Transplantation in Systemic Amyloidosis. Transplantation, 2020, 104, 2035-2047.	0.5	6
7	Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. European Journal of Internal Medicine, 2020, 82, 7-15.	1.0	32
8	Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. International Journal of Molecular Sciences, 2020, 21, 7166.	1.8	15
9	Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis. Frontiers in Neurology, 2020, 11, 605282.	1.1	6
10	Hereditary transthyretin amyloidosis overview. Neurological Sciences, 2022, 43, 595-604.	0.9	39
11	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	1.2	7
12	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	1.4	51
13	A Review of Patisiran (ONPATTROÂ®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2020, 9, 301-315.	1.4	96
14	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	1.4	105
15	Hereditary transthyretin amyloidosis: current treatment. Current Opinion in Neurology, 2020, 33, 553-561.	1.8	11
16	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
17	Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies. Neurology and Therapy, 2020, 9, 317-333.	1.4	59
18	Conventional Molecular Dynamics and Metadynamics Simulation Studies of the Binding and Unbinding Mechanism of TTR Stabilizers AG10 and Tafamidis. ACS Chemical Neuroscience, 2020, 11, 3025-3035.	1.7	7
19	RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. Molecular Pharmaceutics, 2020, 17, 4040-4066.	2.3	22

#	Article	IF	Citations
20	A serine protease secreted from Bacillus subtilis cleaves human plasma transthyretin to generate an amyloidogenic fragment. Communications Biology, 2020, 3, 764.	2.0	12
21	Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet Journal of Rare Diseases, 2020, 15, 348.	1.2	22
22	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences, 2020, 10, 952.	1.1	9
23	Pearls and Oy-sters: Number, weaker, and dizzier due to transthyretin amyloidosis after two liver transplants. Neurology, 2020, 96, 10.1212/WNL.0000000000011289.	1.5	1
24	Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study. Journal of Clinical Medicine, 2020, 9, 1334.	1.0	13
25	Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System, 2020, 25, 85-101.	1.4	12
26	Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease. Cell Death and Disease, 2020, 11, 343.	2.7	21
27	Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 191-199.	1.4	14
28	Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. Lancet Neurology, The, 2020, 19, 522-532.	4.9	36
29	Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment. Neurophysiologie Clinique, 2020, 50, 145-153.	1.0	1
30	Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. Biochemistry, 2020, 59, 2319-2327.	1.2	19
31	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. ACS Medicinal Chemistry Letters, 2020, 11, 1973-1979.	1.3	12
32	Inborn errors of apolipoprotein A-I metabolism. Current Opinion in Lipidology, 2020, 31, 62-70.	1.2	17
33	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	1.4	47
34	Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care . Therapeutics and Clinical Risk Management, 2020, Volume 16, 109-123.	0.9	78
35	Structural Analysis of the Effect of a Dual-FLAG Tag on Transthyretin. Biochemistry, 2020, 59, 1013-1022.	1.2	7
36	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 102.	1.4	11
37	Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. Journal of Clinical Medicine, 2020, 9, 2004.	1.0	239

#	Article	IF	Citations
38	Amyloid Proteins and Peripheral Neuropathy. Cells, 2020, 9, 1553.	1.8	13
39	Half a century of amyloids: past, present and future. Chemical Society Reviews, 2020, 49, 5473-5509.	18.7	345
40	A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 179.	1.2	33
41	Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 2020, 159, 344-363.	6.6	187
43	Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options. British Journal of Pharmacology, 2020, 177, 5336-5356.	2.7	11
44	Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis. Clinical Research in Cardiology, 2020, 109, 949-956.	1.5	5
45	Senile Systemic Amyloidosis Presenting as Hematuria: A Rare Presentation and Review of Literature. Case Reports in Medicine, 2020, 2020, 1-5.	0.3	4
46	Human amyloidosis, still intractable but becoming curable: The essential role of pathological diagnosis in the selection of typeâ€specific therapeutics. Pathology International, 2020, 70, 191-198.	0.6	24
47	Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry, 2020, 59, 1800-1803.	1.2	9
48	Targeting transthyretin â€•Mechanismâ€based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry, 2021, 156, 802-818.	2.1	16
49	Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology, 2021, 96, e412-e422.	1.5	52
50	Proteomic analysis reveals plasma haptoglobin, interferon-Î³, and interleukin-1Î² as potential biomarkers of pediatric refractory epilepsy. Brain and Development, 2021, 43, 431-439.	0.6	9
51	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93
52	Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure, 2021, 8, 652-661.	1.4	43
53	Corneal subâ€basal whorlâ€like nerve plexus: a landmark for early and followâ€up evaluation in transthyretin familial amyloid polyneuropathy. European Journal of Neurology, 2021, 28, 630-638.	1.7	17
54	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology, 2021, 268, 2109-2122.	1.8	141
55	Polyneuropathies. , 2021, , 215-261.		1
56	Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy. European Journal of Neurology, 2021, 28, 982-991.	1.7	9

#	Article	IF	Citations
57	Tafamidis for Cardiac Transthyretin Amyloidosis. Cardiovascular Prevention and Pharmacotherapy, 2021, 3, 1.	0.0	1
58	Neuromuscular amyloidosis: Unmasking the master of disguise. Muscle and Nerve, 2021, 64, 23-36.	1.0	23
59	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.3	9
60	The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis. Frontiers in Pharmacology, 2021, 12, 628184.	1.6	2
61	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	0.5	2
62	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	2.0	29
63	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	0.5	1
64	Unusual Pain Disorders â€“ What Can Be Learned from Them?. Journal of Pain Research, 2020, Volume 13, 3539-3554.	0.8	3
65	Specific postoperative complications of vitrectomy in hereditary transthyretin amyloidosis. European Journal of Ophthalmology, 2022, 32, 1149-1156.	0.7	5
66	Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 3488.	1.8	5
67	Multi-omic analyses in Abyssinian cats with primary renal amyloid deposits. Scientific Reports, 2021, 11, 8339.	1.6	6
68	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	1.1	17
69	ATTRv in Lazio-Italy: A High-Prevalence Region in a Non-Endemic Country. Genes, 2021, 12, 829.	1.0	9
70	<scp>The neuropathy in hereditary transthyretin amyloidosis</scp>: A <scp>narrative review</scp>. Journal of the Peripheral Nervous System, 2021, 26, 155-159.	1.4	30
71	ActualitÃ©s dans les neuropathies amyloÃ¯des. Pratique Neurologique - FMC, 2021, 12, 149-157.	0.1	0
72	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	1.4	12
73	Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation. Neurological Sciences, 2022, 43, 1359-1364.	0.9	10
74	Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management. Current Hematologic Malignancy Reports, 2021, 16, 357-366.	1.2	6

#	Article	IF	Citations
75	Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-7.	1.4	4
76	Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiology and Therapy, 2021, 10, 289-311.	1.1	28
77	Ocular Involvement in Hereditary Transthyretin Amyloidosis: A Case Series Describing Novel Potential Biomarkers. Genes, 2021, 12, 927.	1.0	8
78	Interstitial amyloidosis in sporadic inclusion body myositis. Muscle and Nerve, 2021, 64, 590-594.	1.0	1
80	miRNA regulation of G protein-coupled receptor mediated angiogenic pathways in cancer. Nucleus (India), 0, , 1.	0.9	4
81	Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore. Journal of Neuromuscular Diseases, 2021, 8, 723-733.	1.1	11
82	Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sciences, 2021, 11, 980.	1.1	18
83	Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 226-233.	1.4	23
84	The Ultrastructure of Tissue Damage by Amyloid Fibrils. Molecules, 2021, 26, 4611.	1.7	17
85	Hereditary transthyretin amyloidosis in multi-ethnic Malaysians. Neuromuscular Disorders, 2021, 31, 642-650.	0.3	3
86	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	1.7	23
87	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	1.8	13
88	Domino transplantation for pediatric liver recipients: Obstacles, challenges, and successes. Pediatric Transplantation, 2021, 25, e14114.	0.5	8
89	Transthyretin Amyloidosis Therapies: Guiding the Future. Revista De Investigacion Clinica, 2021, 73, 310-315.	0.2	0
90	Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country. Neuromuscular Disorders, 2021, 31, 1251-1258.	0.3	3
91	Paraproteinemia and neuropathy. Neurological Sciences, 2021, 42, 4489-4501.	0.9	8
92	The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. Orphanet Journal of Rare Diseases, 2021, 16, 25.	1.2	8
93	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews, 2021, 26, 861-879.	1.7	16

#	Article	IF	Citations
94	Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 1178-1185.	1.4	3
96	Conjunctival lymphangiectasia as a biomarker of severe systemic disease in Ser77Tyr hereditary transthyretin amyloidosis. British Journal of Ophthalmology, 2020, 104, 1363-1367.	2.1	8
97	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 339-343.	0.5	10
98	RNA Therapy: Current Status and Future Potential. Chonnam Medical Journal, 2020, 56, 87.	0.5	64
99	Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. Annals of Medicine, 2021, 53, 1787-1796.	1.5	16
100	Genome silencer therapy leading to â€˜regressionâ€™ of cardiac amyloid load on cardiovascular magnetic resonance: a case report. European Heart Journal - Case Reports, 2021, 5, ytab415.	0.3	1
101	Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet Journal of Rare Diseases, 2021, 16, 411.	1.2	24
102	Aggregation-Prone Structural Ensembles of Transthyretin Collected With Regression Analysis for NMR Chemical Shift. Frontiers in Molecular Biosciences, 2021, 8, 766830.	1.6	2
104	Neuropathic Pain: Mechanisms, Clinical Aspects and Treatment Options. , 2020, , 690-731.		0
105	Identification of adhesion-associated DNA methylation patterns in the peripheral nervous system. Experimental and Therapeutic Medicine, 2021, 21, 48.	0.8	0
106	Proposing a minimal set of metrics and methods to predict probabilities of amyloidosis disease and onset age in individuals. Aging, 2020, 12, 22356-22369.	1.4	0
107	Muscle MRI as a Useful Biomarker in Hereditary Transthyretin Amyloidosis: A Pilot Study. Genes, 2021, 12, 1786.	1.0	7
108	High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP. Neurological Sciences, 2022, 43, 3387-3394.	0.9	5
109	Changes in nerve conduction studies predate clinical symptoms onset in early onset Val30Met hereditary ATTR amyloidosis. European Journal of Neurology, 2022, 29, 826-832.	1.7	9
110	Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics, 2021, 18, 2286-2302.	2.1	8
111	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203
112	Antisense therapies in neurological diseases. Brain, 2022, 145, 816-831.	3.7	10
113	Identification of adhesionâ€˜associated DNA methylation patterns in the peripheral nervous system. Experimental and Therapeutic Medicine, 2020, 21, 48.	0.8	3

#	Article	IF	Citations
114	Proposing a minimal set of metrics and methods to predict probabilities of amyloidosis disease and onset age in individuals. Aging, 2020, 12, 22356-22369.	1.4	3
115	CNS Involvement in Hereditary Transthyretin Amyloidosis. Neurology, 2021, 97, 1111-1119.	1.5	30
116	Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion. Journal of Alzheimer's Disease Reports, 2022, 6, 31-41.	1.2	4
117	Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M. Frontiers in Aging Neuroscience, 2021, 13, 786322.	1.7	8
118	Neuromuscular Complications of Systemic Amyloidosis. American Journal of Medicine, 2022, 135, S13-S19.	0.6	2
119	Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis. European Journal of Neurology, 2022, 29, 1477-1487.	1.7	18
121	Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 165-174.	1.4	17
122	Metal complexes for the visualisation of amyloid peptides. Sensors & Diagnostics, 2022, 1, 627-647.	1.9	4
123	Non-Alzheimers Amyloidoses of the Neurological System: Cerebral Amyloid Angiopathy and Familial Amyloid Polyneuropathy. , 0, , .		0
125	A compound score to screen patients with hereditary transthyretin amyloidosis. Journal of Neurology, 2022, , .	1.8	3
126	Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. American Journal of Transplantation, 2022, 22, 1646-1657.	2.6	30
127	Generating Ensembles of Dynamic Misfolding Proteins. Frontiers in Neuroscience, 2022, 16, 881534.	1.4	9
128	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	6.1	64
129	Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria. Frontiers in Neurology, 2022, 13, 844595.	1.1	3
130	Distinct Patterns of Amyloid Pathology in Autopsies of Transthyretin S77Y and A97S Amyloidosis: Significance of Symptomatology and Cell Biology. Journal of Neuropathology and Experimental Neurology, 2022, 81, 363-376.	0.9	3
131	Transthyretin: Its function and amyloid formation. Neurochemistry International, 2022, 155, 105313.	1.9	11
132	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 110-119.	1.4	1
133	Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Nervno-Myshechnye Bolezni, 2021, 11, 12-36.	0.2	0

#	Article	IF	Citations
134	Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies. Journal of Nuclear Cardiology, 2022, 29, 3419-3425.	1.4	5
135	Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. Advances in Therapy, 2022, 39, 2292-2301.	1.3	11
136	RNA therapy: rich history, various applications and unlimited future prospects. Experimental and Molecular Medicine, 2022, 54, 455-465.	3.2	92
140	Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 499-514.	0.4	8
141	Involvement of cranial nerves in ATTR Ile127Val amyloidosis. European Journal of Medical Genetics, 2022, 65, 104524.	0.7	2
142	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv, 2022, 94, 584-595.	0.2	9
143	Acute Mitral Regurgitation Due to Chordae Tendineae Rupture: A Rare Presentation of Cardiac Amyloidosis. American Journal of Case Reports, 0, 23, .	0.3	0
144	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	1.4	55
145	Hereditary transthyretin amyloidosis: aÂcase report. Journal of Medical Case Reports, 2022, 16, .	0.4	2
146	Santalol Isomers Inhibit Transthyretin Amyloidogenesis and Associated Pathologies in Caenorhabditis elegans. Frontiers in Pharmacology, 0, 13, .	1.6	1
147	Gait Characterization and Analysis of Hereditary Amyloidosis Associated with Transthyretin Patients: A Case Series. Journal of Clinical Medicine, 2022, 11, 3967.	1.0	2
148	<scp>Longâ€term</scp> treatment effects of inotersen on <scp>healthâ€related</scp> quality of life in patients with <scp>hATTR</scp> amyloidosis with polyneuropathy: Analysis of the <scp>openâ€label</scp> extension of the <scp>NEUROâ€TTR</scp> trial. Muscle and Nerve, 2022, 66, 438-446.	1.0	3
149	A Study of Familial Amyloid Polyneuropathy Induced by the TTR Val30Leu Mutation in China. European Neurology, 0, , 1-6.	0.6	0
150	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-11.	1.4	1
151	A pilot study of nailfold capillaroscopy in hereditary transthyretin amyloidosis. Scientific Reports, 2022, 12, .	1.6	1
152	Factors associated with increased <scp>healthâ€related</scp> qualityâ€ofâ€life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen. Muscle and Nerve, 2022, 66, 319-328.	1.0	0
153	Cardiac amyloidosis: a review of the literature. Acta Cardiologica, 2022, 77, 683-692.	0.3	8
154	The Frequency of V122I Transthyretin Mutation in a Cohort of African American Individuals With Bilateral Carpal Tunnel Syndrome. Frontiers in Neurology, 0, 13, .	1.1	2

#	Article	IF	Citations
155	Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 18-26.	1.4	97
156	Cutaneous amyloid is a biomarker in early <scp>ATTRv</scp> neuropathy and progresses across disease stages. Annals of Clinical and Translational Neurology, 2022, 9, 1370-1383.	1.7	10
157	Protein Aggregation in Neurodegenerative Diseases. , 2022, , 26-58.		0
158	Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects. Brain Sciences, 2022, 12, 1037.	1.1	4
159	Cardiomyopathy correlates to nerve damage in p. <scp>A117S</scp> lateâ€onset transthyretin amyloid polyneuropathy. Annals of Clinical and Translational Neurology, 0, , .	1.7	3
160	Pupillometric findings in ATTRv patients and carriers: results from a single-centre experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-6.	1.4	1
161	Renal amyloidosis: a new time for a complete diagnosis. Brazilian Journal of Medical and Biological Research, 0, 55, .	0.7	4
162	Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 49-58.	1.4	10
163	Treating hereditary transthyretin amyloidosis: Present & future challenges. Revue Neurologique, 2022, , .	0.6	2
164	Nonviral Delivery of CRISPR/Cas Systems in mRNA Format. Advanced NanoBiomed Research, 2022, 2, .	1.7	8
165	Micro- and Nanoplasticsâ€™ Effects on Protein Folding and Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 10329.	1.8	11
166	Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 81-95.	1.4	3
167	Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 109-118.	1.4	3
168	Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathologica, 2023, 145, 113-126.	3.9	6
169	Macromolecular crowding and supersaturation protect hemodialysis patients from the onset of dialysis-related amyloidosis. Nature Communications, 2022, 13, .	5.8	7
170	Transthyretin Cardiac Amyloidosis. Cardiology Clinics, 2022, 40, 541-558.	0.9	3
171	Leptomeningeal Disease Secondary to Thr60Ala Transthyretin Amyloidosis: Case Report and Review of the Literature. Neurohospitalist, The, 0, , 194187442211278.	0.3	1
173	Advances in CRISPR therapeutics. Nature Reviews Nephrology, 2023, 19, 9-22.	4.1	41

#	Article	IF	Citations
174	Liverâ€directed drugs for t<scp>ransthyretinâ€mediated</scp> amyloidosis. Journal of the Peripheral Nervous System, 2022, 27, 228-237.	1.4	4
175	Suture trabeculotomy ab interno for secondary glaucoma in Japanese patients with Val30Met hereditary transthyretin amyloidosis. Scientific Reports, 2022, 12, .	1.6	1
176	Skeletal muscle 99mTechnetiumâ€pyrophosphate scan: more questions than answers. Muscle and Nerve, 0, , .	1.0	0
177	Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. Medical Review, 2022, 2, 471-500.	0.3	6
178	Maximizing treatment efficacy through patient stratification in neuropathic pain trials. Nature Reviews Neurology, 2023, 19, 53-64.	4.9	17
179	Clinical trials and promising preclinical applications of CRISPR/Cas gene editing. Life Sciences, 2023, 312, 121204.	2.0	4
180	Preimplantation genetic testing for familial amyloid polyneuropathy. Reproductive Health, 2022, 19, .	1.2	0
181	Trajectories of Kidney Function in Patients with ATTRv Treated with Gene Silencers. Genes, 2022, 13, 2236.	1.0	1
182	A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report. BMC Neurology, 2022, 22, .	0.8	0
183	Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 239-243.	1.4	3
184	Follow-up regimens for carriers of hereditary transthyretin variants. Medicina ClÃnica, 2023, 160, 213-217.	0.3	0
185	Prospects for gene replacement therapies in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2023, 19, 39-52.	4.9	7
186	Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications. Brain Sciences, 2022, 12, 1708.	1.1	2
187	Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management. International Journal of General Medicine, 0, Volume 15, 8677-8684.	0.8	0
188	Strategy for genetic analysis in hereditary neuropathy. Revue Neurologique, 2023, 179, 10-29.	0.6	5
189	Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 2022, 52, 2046-2067.	0.5	3
190	Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study. Nephrology Dialysis Transplantation, 0, , .	0.4	1
191	Severe Polyneuropathy in Hereditary Transthyretin Amyloidosis Caused by H90D Variant. Canadian Journal of Neurological Sciences, 2024, 51, 336-338.	0.3	0

#	Article	IF	Citations
192	The Role of Proteolysis in Amyloidosis. International Journal of Molecular Sciences, 2023, 24, 699.	1.8	5
193	Amyloidosis and autonomic failure. , 2023, , 575-583.		0
194	Neurological Manifestations in ATTRv Amyloidosis. , 2023, , 5-17.		0
195	Urological and Kidney Involvements in Amyloidosis. , 2023, , 67-82.		0
196	Ocular Morpho-Functional Evaluation in ATTRv Pre-Symptomatic Carriers: A Case Series. Diagnostics, 2023, 13, 359.	1.3	1
198	Amylose Ã transthyrÃ©tine. , 2022, , 45-52.		0
199	<scp>Ser77Tyr</scp> transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features. Annals of Clinical and Translational Neurology, 2023, 10, 553-567.	1.7	0
200	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
201	Hint approach on Transthyretin folding/unfolding mechanism comprehension. Computers in Biology and Medicine, 2023, 155, 106667.	3.9	2
202	Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 303-312.	1.4	1
203	Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy. Drug, Healthcare and Patient Safety, 0, Volume 15, 51-62.	1.0	2
204	How should we diagnose CNS involvement of transthyretin amyloidosis?. Revue Neurologique, 2023, 179, 373-375.	0.6	0
205	Follow-up regimens for carriers of hereditary transthyretin variants. Medicina ClÃ¬nica (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	0.1	0
206	A molecular basis for tetramer destabilization and aggregation of transthyretin <scp>Ala97Ser</scp>. Protein Science, 2023, 32, .	3.1	4
207	Chemistry, structureÂand function of approved oligonucleotide therapeutics. Nucleic Acids Research, 2023, 51, 2529-2573.	6.5	110
209	Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis. Neurology, 2023, 100, .	1.5	6
210	Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis. Journal of Neurology, 0, , .	1.8	1
211	First description of Portuguese patients with cardiac amyloidosis and p.Val142Ile: more evidence of an â€œAfrican variantâ€•in Caucasians. Scandinavian Cardiovascular Journal, 2023, 57, .	0.4	0

#	Article	IF	Citations
212	Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition. Arquivos De Neuro-Psiquiatria, 2023, 81, 308-321.	0.3	0
219	Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy. Journal of Neurology, 2023, 270, 4827-4840.	1.8	2
221	Editorial: Updating amyloid neuropathy knowledge: from diagnosis to treatment. Frontiers in Neurology, 0, 14, .	1.1	0
255	Combining Neighbor Models to Improve Predictions of Age of Onset of ATTRv Carriers. Lecture Notes in Computer Science, 2023, , 286-297.	1.0	0
259	Liver transplantation: the recipient. , 2024, , 997-1283.		0